Other candidates include the glycoengineered anti-CD19 antibody MOR208, which is under investigation in refractory B-cell non-Hodgkin lymphoma, and the glycoengineered anti-CCR4 antibody KW-0761, mogamulizumab, tested for T cell lymphoma.27,28 It is however important to bear in mind that enhanced activity, especially in the context of CAR T cells which can come with a severe side effect profile,4 carries the risk of more dismal side effects too. Here, CCR4 is linked to B-cell non-Hodgkin lymphoma.